Practical management of patients with myelofibrosis receiving ruxolitinib
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Practical management of patients with myelofibrosis receiving ruxolitinib
Authors
Keywords
-
Journal
Expert Review of Hematology
Volume 6, Issue 5, Pages 511-523
Publisher
Informa UK Limited
Online
2013-10-02
DOI
10.1586/17474086.2013.827413
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium
- (2012) Omar Abdel-Wahab et al. AMERICAN JOURNAL OF HEMATOLOGY
- Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly
- (2012) O. Benjamini et al. BLOOD
- Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
- (2012) A. Eghtedar et al. BLOOD
- Guideline for the diagnosis and management of myelofibrosis
- (2012) John T. Reilly et al. BRITISH JOURNAL OF HAEMATOLOGY
- One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
- (2012) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Ruxolitinib for Myelofibrosis
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- New mutations and pathogenesis of myeloproliferative neoplasms
- (2011) W. Vainchenker et al. BLOOD
- Extramedullary hematopoiesis involving the central nervous system and surrounding structures
- (2011) Viktor Zherebitskiy et al. HUMAN PATHOLOGY
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- (2011) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- How I treat splenomegaly in myelofibrosis
- (2011) F Cervantes Blood Cancer Journal
- Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
- (2010) S. T. Oh et al. BLOOD
- Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
- (2010) S. Thepot et al. BLOOD
- Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis
- (2010) F. Passamonti et al. BLOOD
- Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis
- (2010) S. Verstovsek CLINICAL CANCER RESEARCH
- Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans
- (2010) A. D. Shilling et al. DRUG METABOLISM AND DISPOSITION
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic options for patients with myelofibrosis in blast phase
- (2010) John Mascarenhas et al. LEUKEMIA RESEARCH
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- How I treat symptomatic splenomegaly in patients with myelofibrosis
- (2009) R. A. Mesa BLOOD
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics
- (2009) Ayalew Tefferi et al. Nature Reviews Clinical Oncology
- Portal hypertension secondary to myelofibrosis with myeloid metaplasia: A study of 13 cases
- (2009) Mohannad Abu-Hilal et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment
- (2008) Omar I. Abdel-Wahab et al. Annual Review of Medicine
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Risk factors for leukemic transformation in patients with primary myelofibrosis
- (2008) Jocelin Huang et al. CANCER
- A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
- (2008) A Quintás-Cardama et al. LEUKEMIA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started